PROJECT PARTNERS

PARIS is a transdisciplinary research project that brings together five research groups located in 4 European countries, to develop diagnostic tools and improve the treatment options for high-grade serous ovarian cancer. The expertise of the partners ranges from clinical medicine and experimental models, over single cell technology, drug screening, and artificial intelligence, to medical ethics.

benno.jpeg

DR. BENNO SCHWIKOWSKI

Computational analysis, project coordination

The Computational Systems Biomedicine lab in the Department of Computational Biology at Institut Pasteur, Paris, France, develops algorithms to detect and classify transcriptomic signatures of resistance in clinical and organoid samples, and generates computational predictions for the drugs that eliminate major resistant subpopulations.

anna.jpg

DR. ANNA VÄHÄRAUTIO

Single cell transcriptomics

The Single-cell transcriptomics of cancer group at the University of Helsinki, Finland, measures patient-specific heterogeneity in clinical and organoid samples at the level of single cells, and contributes to the detection and classification of transcriptomic signatures.

krister_edited.jpg

PR. KRISTER WENNERBERG

Organoid models, drug screening

The Wennerberg Group at the Biotech Research & Innovation Centre at the University of Copenhagen, Denmark, develops experimental organoid models for ovarian cancer patient-specific heterogeneity, and experimentally screens for drugs that kill the major resistant subpopulations.

line_edited.jpg

PR. LINE BJØRGE

Clinical applications

Line Bjørge’s group at the Haukeland University Hospital in Bergen, Norway, provides expertise and knowledge about the complex clinical context in which resistant subpopulations are identified, and drugs are being used to eliminate them.

emmet.jpg

PR. EMMET MC CORMACK

Ovarian cancer models

The Translational Molecular Imaging group at the University of Bergen, Norway, provides leading-edge patient-derived xenograft models and multimodal imaging to evaluate candidate drugs against resistant subpopulations.

veikko.jpg

PR. VEIKKO LAUNIS, PHD

Ethical aspects

Professor Launis and his collaborators at the Department of Clinical Medicine at the University of Turku, Finland, provide guidance on ethical aspects, such as human dignity, genetics and ethics of clinical research, and palliative care.